L-701324
Names | |
---|---|
IUPAC name
7-Chloro-4-hydroxy-3-(3-phenoxyphenyl)-1H-quinolin-2-one
| |
Identifiers | |
3D model (JSmol)
|
|
ChEBI | |
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.162.301 |
EC Number |
|
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C21H14ClNO3 | |
Molar mass | 363.80 g·mol−1 |
Hazards | |
GHS labelling:[1] | |
Warning | |
H315, H319, H335 | |
P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, P501 | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
L-701324 is an antagonist of the NMDA receptor. It appears to have activity in animal models of depression.
Pharmacology
[edit]L-701324 appears to be an antagonist of the NMDA receptor and acts at the glycine binding site.[2] This means that it prevents the receptor from activating by blocking the binding of glycine, a required co-agonist in addition to glutamate.
Potential use as an antidepressant
[edit]L-701324 exhibited antidepressant behavior in mice by reducing depression-like behavior caused by the forced swimming test, the tail suspension test, and the chronic unpredictable mild stress model.[3]
In another animal study, a combination of an adenosine receptor antagonist, such as caffeine, with an NMDA receptor antagonist, such as L-701324, showed a synergistic effect that might have use as an antidepressant.[4]
References
[edit]- ^ "7-Chloro-4-hydroxy-3-(3-phenoxyphenyl)quinolin-2(1H)-one". PubChem. U.S. National Library of Medicine.
- ^ Priestley T, Laughton P, Macaulay AJ, Hill RG, Kemp JA (1996). "Electrophysiological characterisation of the antagonist properties of two novel NMDA receptor glycine site antagonists, L-695,902 and L-701,324". Neuropharmacology. 35 (11): 1573–1581. doi:10.1016/s0028-3908(96)00141-4. PMID 9025105.
- ^ Liu L, Ji CH, Wang Y, Zhao J, Liu Y, Tang WQ, et al. (February 2021). "Antidepressant-like activity of L-701324 in mice: A behavioral and neurobiological characterization". Behavioural Brain Research. 399: 113038. doi:10.1016/j.bbr.2020.113038. PMID 33276033.
- ^ Serefko A, Szopa A, Wlaź A, Wośko S, Wlaź P, Poleszak E (April 2016). "Synergistic antidepressant-like effect of the joint administration of caffeine and NMDA receptor ligands in the forced swim test in mice". Journal of Neural Transmission. 123 (4): 463–472. doi:10.1007/s00702-015-1467-4. PMC 4805709. PMID 26510772.